![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
SM De Morais, GR Wilkinson, J Blaisdell, UA Meyer, K Nakamura and JA Goldstein
National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709.
A genetic polymorphism in the metabolism of the anticonvulsant drug (S)- mephenytoin has been well documented in humans. There are marked interracial differences in the frequency of the poor metabolizer phenotype, which comprises 2-5% of Caucasian but 18-23% of Asian populations. We have recently reported that the principal genetic defect responsible for the poor metabolizer phenotype is a single-base pair mutation in exon 5 of CYP2C19 (CYP2C19m), which accounts for approximately 75-83% of the defective alleles in both Japanese and Caucasians subjects. In the present study, we have identified a new mutation (CYP2C19m2) in Japanese poor metabolizers, consisting of a guanine to adenine mutation at position 636 of exon 4 of CYP2C19, which creates a premature stop codon. Genotyping of seven Japanese poor metabolizers who were not homozygous for the previously described CYP2C19m defect (now designated CYP2C19m1) indicated that they were either homozygous for the new defect (CYP2C19m2/CYP2C19m2) or heterozygous (CYP2C19m1/CYP2C19m2) for the two defects. CYP2C19m1 accounts for 25 of 34 alleles in Japanese poor metabolizers, whereas CYP2C19m2 accounts for the remaining nine alleles. Hence, CYP2C19m1 and CYP2C19m2 explain 100% of the available Japanese poor metabolizers (34 alleles). In contrast, the CYP2C19m2 defect was not detected in nine Caucasian poor metabolizers (83% of available poor metabolizer alleles were CYP2C19m1), indicating the existence of another, as yet unidentified, mutation. Genetic testing of the families of two Japanese poor metabolizer probands showed that coinheritance of the CYP2C19m1 and CYP2C19m2 alleles was concordant with the autosomal recessive inheritance of the poor metabolizer phenotype.
This article has been cited by other articles:
|
|
 |
|
  M. Hiratsuka, Y. Hinai, T. Sasaki, Y. Konno, K. Imagawa, M. Ishikawa, and M. Mizugaki Characterization of Human Cytochrome P450 Enzymes Involved in the Metabolism of Cilostazol Drug Metab. Dispos., October 1, 2007; 35(10): 1730 - 1732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Court A Pharmacogenomics Primer J. Clin. Pharmacol., September 1, 2007; 47(9): 1087 - 1103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Zandvliet, A. D.R. Huitema, W. Copalu, Y. Yamada, T. Tamura, J. H. Beijnen, and J. H.M. Schellens CYP2C9 and CYP2C19 Polymorphic Forms Are Related to Increased Indisulam Exposure and Higher Risk of Severe Hematologic Toxicity Clin. Cancer Res., May 15, 2007; 13(10): 2970 - 2976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Johnson, I. H. Song, K. K. Adkison, J. Borland, L. Fang, Y. Lou, M. M. Berrey, A. N. Nafziger, S. C. Piscitelli, and J. S. Bertino Jr Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified cooperstown 5 + 1 cocktail. J. Clin. Pharmacol., May 1, 2006; 46(5): 577 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Tomalik-Scharte, A. Jetter, M. Kinzig-Schippers, A. Skott, F. Sorgel, T. Klaassen, D. Kasel, S. Harlfinger, O. Doroshyenko, D. Frank, et al. EFFECT OF PROPIVERINE ON CYTOCHROME P450 ENZYMES: A COCKTAIL INTERACTION STUDY IN HEALTHY VOLUNTEERS Drug Metab. Dispos., December 1, 2005; 33(12): 1859 - 1866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ohnishi, S. Murakami, S. Akizuki, J. Mochizuki, H. Echizen, and I. Takagi In Vivo Metabolic Activity of CYP2C19 and CYP3A in Relation to CYP2C19 Genetic Polymorphism in Chronic Liver Disease J. Clin. Pharmacol., November 1, 2005; 45(11): 1221 - 1229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Uno, N. Yasui-Furukori, T. Takahata, K. Sugawara, and T. Tateishi Lack of Significant Effect of Grapefruit Juice on the Pharmacokinetics of Lansoprazole and Its Metabolites in Subjects With Different CYP2C19 Genotypes J. Clin. Pharmacol., June 1, 2005; 45(6): 690 - 694. [Full Text]
|
|
|
|
 |
|
 W. Steimer, K. Zopf, S. von Amelunxen, H. Pfeiffer, J. Bachofer, J. Popp, B. Messner, W. Kissling, and S. Leucht Amitriptyline or Not, That Is the Question: Pharmacogenetic Testing of CYP2D6 and CYP2C19 Identifies Patients with Low or High Risk for Side Effects in Amitriptyline Therapy Clin. Chem., February 1, 2005; 51(2): 376 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Katoh, T. Matsui, M. Nakajima, C. Tateno, M. Kataoka, Y. Soeno, T. Horie, K. Iwasaki, K. Yoshizato, and T. Yokoi EXPRESSION OF HUMAN CYTOCHROMES P450 IN CHIMERIC MICE WITH HUMANIZED LIVER Drug Metab. Dispos., December 1, 2004; 32(12): 1402 - 1410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Giraud, A. Tran, E. Rey, J. Vincent, J.-M. Treluyer, and G. Pons IN VITRO CHARACTERIZATION OF CLOBAZAM METABOLISM BY RECOMBINANT CYTOCHROME P450 ENZYMES: IMPORTANCE OF CYP2C19 Drug Metab. Dispos., November 1, 2004; 32(11): 1279 - 1286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Yasui-Furukori, M. Saito, T. Uno, T. Takahata, K. Sugawara, and T. Tateishi Effects of Fluvoxamine on Lansoprazole Pharmacokinetics in Relation to CYP2C19 Genotypes J. Clin. Pharmacol., November 1, 2004; 44(11): 1223 - 1229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kim, J. A. Johnson, and H. Derendorf Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms J. Clin. Pharmacol., October 1, 2004; 44(10): 1083 - 1105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. C. DeLozier, C.-C. Tsao, S. J. Coulter, J. Foley, J. A. Bradbury, D. C. Zeldin, and J. A. Goldstein CYP2C44, a New Murine CYP2C That Metabolizes Arachidonic Acid to Unique Stereospecific Products J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 845 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Steimer, K. Zopf, S. von Amelunxen, H. Pfeiffer, J. Bachofer, J. Popp, B. Messner, W. Kissling, and S. Leucht Allele-Specific Change of Concentration and Functional Gene Dose for the Prediction of Steady-State Serum Concentrations of Amitriptyline and Nortriptyline in CYP2C19 and CYP2D6 Extensive and Intermediate Metabolizers Clin. Chem., September 1, 2004; 50(9): 1623 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Q. P. Yin, B. Tomlinson, A. H. L. Chow, M. M. Y. Waye, and M. S. S. Chow Omeprazole as a CYP2C19 Marker in Chinese Subjects: Assessment of Its Gene-Dose Effect and Intrasubject Variability J. Clin. Pharmacol., June 1, 2004; 44(6): 582 - 589. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Sinues, A. Fanlo, M. L. Bernal, M. Val, and E. Mayayo Omeprazole treatment: genotoxicity biomarkers, and potential to induce CYP1A2 activity in humans Human and Experimental Toxicology, March 1, 2004; 23(3): 107 - 113. [Abstract] [PDF]
|
|
|
|
|
|
B.-N. Yu, G.-L. Chen, N. He, D.-S. Ouyang, X.-P. Chen, Z.-Q. Liu, and H.-H. Zhou PHARMACOKINETICS OF CITALOPRAM IN RELATION TO GENETIC POLYMORPHISM OF CYP2C19 Drug Metab. Dispos., October 1, 2003; 31(10): 1255 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Yamane MagiProbe: a novel fluorescence quenching-based oligonucleotide probe carrying a fluorophore and an intercalator Nucleic Acids Res., October 1, 2002; 30(19): e97 - e97. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Raucy, L. Mueller, K. Duan, S. W. Allen, S. Strom, and J. M. Lasker Expression and Induction of CYP2C P450 Enzymes in Primary Cultures of Human Hepatocytes J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 475 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Zhang, Y. Ramamoorthy, R. F. Tyndale, S. D. Glick, I. M. Maisonneuve, M. E. Kuehne, and E. M. Sellers Metabolism of 18-Methoxycoronaridine, an Ibogaine Analog, to 18-Hydroxycoronaridine by Genetically Variable CYP2C19 Drug Metab. Dispos., June 1, 2002; 30(6): 663 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Glauser Advancing the Medical Management of Epilepsy: Disease Modification and Pharmacogenetics J Child Neurol, January 1, 2002; 17(1_suppl): S85 - S93. [Abstract] [PDF]
|
|
|
|
|
|
K. Kosuge, Y. Jun, H. Watanabe, M. Kimura, M. Nishimoto, T. Ishizaki, and K. Ohashi Effects of CYP3A4 Inhibition by Diltiazem on Pharmacokinetics and Dynamics of Diazepam in Relation to CYP2C19 Genotype Status Drug Metab. Dispos., October 1, 2001; 29(10): 1284 - 1289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hersberger, J. Marti-Jaun, K. Rentsch, and E. Hanseler Two Single-Tube Tetra-Primer Assays to Detect the CYP2C19*2 and *3 Alleles of S-Mephenytoin Hydroxylase Clin. Chem., April 1, 2001; 47(4): 772 - 774. [Full Text] [PDF]
|
|
|
|
|
|
S. Gerbal-Chaloin, J.-M. Pascussi, L. Pichard-Garcia, M. Daujat, F. Waechter, J.-M. Fabre, N. Carrère, and P. Maurel Induction of CYP2C Genes in Human Hepatocytes in Primary Culture Drug Metab. Dispos., March 1, 2001; 29(3): 242 - 251. [Abstract] [Full Text]
|
|
|
|
|
|
K. Kobayashi, M. Kogo, M. Tani, N. Shimada, T. Ishizaki, S. Numazawa, T. Yoshida, T. Yamamoto, Y. Kuroiwa, and K. Chiba Role of CYP2C19 in Stereoselective Hydroxylation of Mephobarbital by Human Liver Microsomes Drug Metab. Dispos., January 1, 2001; 29(1): 36 - 40. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. Bartsch, U. Nair, A. Risch, M. Rojas, H. Wikman, and K. Alexandrov Genetic Polymorphism of CYP Genes, Alone or in Combination, as a Risk Modifier of Tobacco-related Cancers Cancer Epidemiol. Biomarkers Prev., January 1, 2000; 9(1): 3 - 28. [Abstract] [Full Text]
|
|
|
|
|
|
M. Garcia-Barcelo, L.-Y. Chow, H. F. K. Chiu, Y. K. Wing, D. T. S. Lee, K. L. Lam, and M. M. Y. Waye Frequencies of Defective CYP2C19 Alleles in a Hong Kong Chinese Population: Detection of the Rare Allele CYP2C19*4 Clin. Chem., December 1, 1999; 45(12): 2273 - 2274. [Full Text] [PDF]
|
|
|
|
|
|
G. C. Ibeanu, J. Blaisdell, R. J. Ferguson, B. I. Ghanayem, K. Brøsen, S. Benhamou, C. Bouchardy, G. R. Wilkinson, P. Dayer, and J. A. Goldstein A Novel Transversion in the Intron 5 Donor Splice Junction of CYP2C19 and a Sequence Polymorphism in Exon 3 Contribute to the Poor Metabolizer Phenotype for the Anticonvulsant Drug S-Mephenytoin J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 635 - 640. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Kortunay, A. Bozkurt, L. Bathum, N. E Basci, M. Çalgüneri, and K. Brøsen CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus Ann Rheum Dis, March 1, 1999; 58(3): 182 - 185. [Abstract] [Full Text]
|
|
|
|
|
|
G. C. Ibeanu, J. A. Goldstein, U. Meyer, S. Benhamou, C. Bouchardy, P. Dayer, B. I. Ghanayem, and J. Blaisdell Identification of New Human CYP2C19 Alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian Poor Metabolizer of Mephenytoin J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1490 - 1495. [Abstract] [Full Text]
|
|
|
|
|
|
R. J. Ferguson, S. M.F. De Morais, S. Benhamou, C. Bouchardy, J. Blaisdell, G. Ibeanu, G. R. Wilkinson, T. C. Sarich, J. M. Wright, P. Dayer, et al. A New Genetic Defect in Human CYP2C19: Mutation of the Initiation Codon Is Responsible for Poor Metabolism of S-Mephenytoin J. Pharmacol. Exp. Ther., January 1, 1998; 284(1): 356 - 361. [Abstract] [Full Text]
|
|
|
|
|
|
H. Yamazaki, K. Inoue, P. M. Shaw, W. J. Checovich, F. P. Guengerich, and T. Shimada Different Contributions of Cytochrome P450 2C19 and 3A4 in the Oxidation of Omeprazole by Human Liver Microsomes: Effects of Contents of These Two Forms in Individual Human Samples J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 434 - 442. [Abstract] [Full Text]
|
|
|
|
|
|
E. Koyama, K. Chiba, M. Tani, and T. Ishizaki J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1199 - 1210. [Abstract] [Full Text]
|
|
|
|
|
|
Z.-S. Xiao, J. A. Goldstein, H.-G. Xie, J. Blaisdell, W. Wang, C.-H. Jiang, F.-X. Yan, N. He, S.-L. Huang, Z.-H. Xu, et al. Differences in the Incidence of the CYP2C19 Polymorphism Affecting the S-Mephenytoin Phenotype in Chinese Han and Bai Populations and Identification of a New Rare CYP2C19 Mutant Allele J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 604 - 609. [Abstract] [Full Text]
|
|
|
|
|
|
K. Kobayashi, K. Chiba, T. Yagi, N. Shimada, T. Taniguchi, T. Horie, M. Tani, T. Yamamoto, T. Ishizaki, and Y. Kuroiwa Identification of Cytochrome P450 Isoforms Involved in Citalopram N-Demethylation by Human Liver Microsomes J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 927 - 933. [Abstract] [Full Text]
|
|
|
|
|
|
M. W. Linder, R. A. Prough, and R. Valdes Jr. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency Clin. Chem., February 1, 1997; 43(2): 254 - 266. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
